<DOC>
	<DOCNO>NCT00921414</DOCNO>
	<brief_summary>Randomized , open-label , phase III study evaluate efficacy rituximab maintenance therapy patient age 18 65 year inclusive undergoing first-line treatment mantle cell lymphoma exhibit response autologous transplantation .</brief_summary>
	<brief_title>Mantel Cell Lymphoma Efficacy Rituximab Maintenance</brief_title>
	<detailed_description>Demonstration superiority term 4-year event-free survival ( EFS ) Rituximab maintenance therapy compare post-autograft surveillance patient age 18-65 year inclusive , treat R-DHAP autologous transplantation MCL first-line therapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>mantle cell lymphoma Initial immunophenotyping CD20 CD5 . CD20+ . ( 11 ; 14 ) karyote , FISH , molecular biology immunohistochemistry ( Bcl1 ) Patient previous treat . At least one tumor site accessible assessment Aged &gt; 18 year &lt; 65 ECOG &lt; = 2 . No neoplasms apart resect basal cell carcinoma situ carcinoma . sign informed consent FEVG 50 % type lymphoma ECOG &gt; = 3 relapse serology VIH + Hepatite + diabetis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Mantle cell lymphoma</keyword>
	<keyword>R DHAP</keyword>
	<keyword>ASCT</keyword>
	<keyword>Rituximab Maintenance</keyword>
</DOC>